Skip to main content

Table 3 Linear logistic regression models of time weighted AUC0–24 h by adverse event (N = 1465 participants)

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Adverse event

Estimate (standard error)

Odds ratio (95% CI)

P value

Insomnia/sleep disorders

− 0.0919 (0.0479)

0.912 (0.830, 1.002)

0.0549

Serious adverse events

0.0470 (0.0285)

1.048 (0.991, 1.108)

0.0989

Psychotic symptoms

0.2671 (0.1959)

1.306 (0.890, 1.917)

0.1728

Muscle spasm

0.1047 (0.0810)

1.110 (0.947, 1.301)

0.1963

Anxiety

0.0611 (0.0475)

1.063 (0.968, 1.167)

0.1987

Rash/dermatitis/urticaria

− 0.0363 (0.0466)

0.964 (0.880, 1.057)

0.4356

Diarrhea

0.0267 (0.0441)

1.027 (0.942, 1.120)

0.5444

Falls and injuries

− 0.0171 (0.0353)

0.983 (0.917, 1.053)

0.6274

Pain in the extremity

0.0270 (0.0733)

1.027 (0.890, 1.186)

0.7128

Syncope-like (with loss of consciousness)

0.0188 (0.0557)

1.019 (0.914, 1.137)

0.7355

Rash event of clinical interest

0.0176 (0.0585)

1.018 (0.907, 1.141)

0.7639

Weight decreased

− 0.0106 (0.0483)

0.989 (0.900, 1.088)

0.8260

Suicidal ideation

− 0.0041 (0.0498)

0.996 (0.903, 1.098)

0.9342

  1. AUC0-24 h, area under the concentration time curve within a 24-h dosing interval at steady state